Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer

Breast Cancer Clinical Trial

Official title:

A Clinical Study of Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR Positive HER2 Positive Breast Cancer

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06276868
• Other study ID #: HELEN-017
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: June 1, 2024
• Est. completion date: June 1, 2029

Study information

• Verified date: November 2023
• Source: Henan Cancer Hospital
• Contact: Zhenzhen Liu
• Phone: 0371-65587005
• Email: liuzhenzhen73[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is intended to carry out a single arm, prospective, open clinical study, and use Darsilide combined with endocrine therapy, Trastuzumab and Patuzumab to treat early or locally advanced breast cancer of TPBC before surgery. It is intended to further explore the efficacy and safety of the new adjuvant treatment for TPBC patients with step-down therapy.

Description:

This study is intended to carry out a single arm, prospective, open clinical study, and use Darsilide combined with endocrine therapy, Trastuzumab and Patuzumab to treat early or locally advanced breast cancer of TPBC before surgery. It is intended to further explore the efficacy and safety of the new adjuvant treatment for TPBC patients with step-down therapy.

All participants received 150mg of darcilib once a day. Take it continuously for 21 days, then stop taking it for 7 days, with a treatment cycle of 28 days.Letrozole 2.5mg once daily (premenopausal patients treated with OFS).Trastuzumab (8mg/kg first dose, 6mg/kg sequential) and Patuzumab (840mg first dose, 420mg/kg sequential) were administered intravenously every 3 weeks, with all patients receiving 6 cycles of treatment. After starting treatment and before surgery, subjects will be monitored through breast MRI to evaluate clinical tumor remission. The primary endpoint was the pCR rate in the group receiving darcilib+letrozole+HP treatment, defined as the proportion of patients who achieved pCR after surgery after neoadjuvant therapy.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 66
• Est. completion date: June 1, 2029
• Est. primary completion date: July 1, 2025
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Female initial treatment patients aged = 18 years and = 70 years.

2. ECOG score 0-1 points.

3. Pathologically confirmed as invasive breast cancer, with tumor staging of cT2-3/N0-3M0.

4. HR positive HER-2 positive.

5. The main organs function normally and meet the following standards:

(1)The blood routine examination standards must comply with:ANC =1.5×10 9/L;PLT =100×109/L;Hb =90g/L. (2)Biochemical examination must meet the following standards: TBIL = 1.5 Upper limit of normal value (ULN);ALT and AST = 1.5 times the upper limit of normal value (ULN);Alkaline phosphatase = 2.5 times the upper limit of normal value (ULN);BUN and Cr = 1.5 × ULN and creatinine clearance rate = 50 mL/min; (3)Cardiac ultrasound and echocardiography: Left ventricular ejection fraction (LVEF = 50%).

6. For female patients who have not undergone menopause or surgical sterilization: Agree to abstain or use effective contraceptive methods during the treatment period and at least 7 months after the last administration during the study treatment.

7. Volunteer to join this study and sign an informed consent form.

Exclusion Criteria:

1. Stage IV (metastatic) breast cancer.

2. inflammatory breast cancer.

3. Previously received anti-tumor therapy or radiation therapy for any malignant tumor, excluding cured cervical cancer in situ, basal cell carcinoma, or squamous cell carcinoma.

4. Simultaneously receiving anti-tumor therapies in other clinical trials, including endocrine therapy, bisphosphate therapy, or immunotherapy.

5. The patient had undergone major surgical procedures unrelated to breast cancer within 4 weeks before enrollment, or the patient has not fully recovered from such surgical procedures.

6. Individuals who have previously suffered from clinically significant lung diseases, including but not limited to interstitial pneumonia, pneumonia, pulmonary fibrosis, and radiation pneumonia (excluding radiation changes that do not require corrective treatment), or those who have been found to have such diseases through screening period examinations.

7. Serious heart disease or discomfort, including but not limited to the following diseases:

(1)Confirmed history of heart failure or systolic dysfunction (LVEF<50%). (2)High risk uncontrolled arrhythmia(atrial tachycardia,ventricular tachycardia,Higher level atrioventricular block); (3)Angina pectoris requiring treatment with anti angina drugs; (4)Clinically significant heart valve disease; (5)ECG shows transmural myocardial infarction; (6)Poor control of hypertension (systolic blood pressure>180 mmHg and/or diastolic blood pressure>100 mmHg); 8. Inability to swallow, intestinal obstruction, or other factors that affect drug administration and absorption.

9. Individuals with a known history of allergies to the drug components of this protocol;Having a history of immunodeficiency, including HIV testing positive, or suffering from other acquired or congenital immunodeficiency diseases, or having a history of organ transplantation.

10. Pregnant and lactating female patients, those with fertility and positive baseline pregnancy test results, or those of childbearing age who are unwilling to take effective contraceptive measures during the entire trial period and within 7 months after the last study medication.

11. Suffering from severe comorbidities or other comorbidities that may interfere with the planned treatment, or any other situation where the researcher deems the patient unsuitable to participate in this study.

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms
• HER2-positive Breast Cancer

Intervention

Drug:
• Dalcilib+letrozole+HP treatment group
All participants received 150mg of darcilib once a day. Take it continuously for 21 days, then stop taking it for 7 days, with a treatment cycle of 28 days. Letrozole 2.5mg once daily (premenopausal patients treated with OFS); Trastuzumab (8mg/kg first dose, 6mg/kg sequential) and Patuzumab (840mg first dose, 420mg/kg sequential) were administered intravenously every 3 weeks, with all patients receiving 6 cycles of treatment.

Locations

Country	Name	City	State
China	Henan cacer hospital	Henan	Henan

Sponsors (1)

Lead Sponsor	Collaborator
Henan Cancer Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	pathologic complete response	The proportion of patients in this group who achieved pCR after surgery after neoadjuvant therapy	Immediately after surgery
Secondary	Adverse event occurrence	The incidence and severity of adverse events (including serious adverse events)	At the end of one Cycle (each cycle is 28 days)
Secondary	objective response rate	The proportion of patients who achieved CR or PR before surgery after neoadjuvant therapy among all subjects	At the end of Cycle 6 (each cycle is 28 days)
Secondary	Residual cancer burden	Proportion of patients with residual cancer burden score of 0-1 after surgery	Immediately after surgery
Secondary	Event free survival	The time interval between enrollment and the first recording of related events, including preoperative disease progression, postoperative disease recurrence, and death from any cause.	5 years after surgery
Secondary	Disease free survival	The time interval between the first day without disease (surgery date) and the first recording of related events, including postoperative disease recurrence and death from any cause.	5 years after surgery
Secondary	Distant disease/recurrence free survival	The time interval between the first day without disease ( surgery date) and the first occurrence of distant recurrence.	5 years after surgery